Asciminib (Scemblix): CML Treatment for T315I Mutation
Asciminib is a groundbreaking treatment for Chronic Myeloid Leukemia (CML) with a mechanism of action distinct from all previously approved Tyrosine Kinase Inhibitors (TKIs). It is the first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor.
While traditional TKIs (like imatinib) bind to the ATP site of the BCR-ABL1 oncoprotein, Asciminib (Scemblix) binds to the myristoyl pocket. This acts like a "second lock" on the cancer protein, turning it off. This unique mechanism helps overcome resistance caused by mutations and reduces off-target side effects commonly seen with other drugs.
It is specifically designed for patients who have exhausted other treatment options or carry the T315I mutation.
Indications
- Ph+ CML in Chronic Phase: Treatment of adult patients previously treated with two or more tyrosine kinase inhibitors (TKIs).
- Ph+ CML with T315I Mutation: Treatment of adult patients with the T315I mutation, which confers resistance to most other TKIs.
Dosage and administration
Strict fasting rules apply: Avoid food for 2 hours before and 1 hour after taking the dose.
- Standard Dose (Post-2 TKIs):
- 80 mg taken once daily.
- OR 40 mg taken twice daily (every 12 hours).
- For T315I Mutation: 200 mg taken twice daily.
- Instructions: Swallow tablets whole with water. Do not crush or chew.
- Pancreatitis History: Use with caution due to risk of serum lipase and amylase elevation.
- Pregnancy and Breastfeeding (potential for fetal harm).
- Hypersensitivity to asciminib.
Regular monitoring of blood counts and pancreatic enzymes is required.
- Myelosuppression: Thrombocytopenia, neutropenia, and anemia.
- Pancreatic Toxicity: Elevated lipase and amylase levels. Patients should report severe abdominal pain immediately.
- Cardiovascular: Hypertension (high blood pressure).
- General: Musculoskeletal pain, fatigue, upper respiratory tract infections, headache.
